Literature DB >> 12407407

Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Hung T Khong1, Nicholas P Restifo.   

Abstract

The idea that tumors must "escape" from immune recognition contains the implicit assumption that tumors can be destroyed by immune responses either spontaneously or as the result of immunotherapeutic intervention. Simply put, there is no need for tumor escape without immunological pressure. Here, we review evidence supporting the immune escape hypothesis and critically explore the mechanisms that may allow such escape to occur. We discuss the idea that the central engine for generating immunoresistant tumor cell variants is the genomic instability and dysregulation that is characteristic of the transformed genome. "Natural selection" of heterogeneous tumor cells results in the survival and proliferation of variants that happen to possess genetic and epigenetic traits that facilitate their growth and immune evasion. Tumor escape variants are likely to emerge after treatment with increasingly effective immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12407407      PMCID: PMC1508168          DOI: 10.1038/ni1102-999

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  100 in total

Review 1.  Clinical significance of the determination of angiogenic factors.

Authors:  M Toi; T Taniguchi; Y Yamamoto; T Kurisaki; H Suzuki; T Tominaga
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

2.  Dendritic cells hold promise for immunotherapy.

Authors:  G Girolomoni; P Ricciardi-Castagnoli
Journal:  Immunol Today       Date:  1997-03

3.  Effect of interleukin-10 on dendritic cell maturation and function.

Authors:  T De Smedt; M Van Mechelen; G De Becker; J Urbain; O Leo; M Moser
Journal:  Eur J Immunol       Date:  1997-05       Impact factor: 5.532

4.  Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules.

Authors:  F Y Yue; R Dummer; R Geertsen; G Hofbauer; E Laine; S Manolio; G Burg
Journal:  Int J Cancer       Date:  1997-05-16       Impact factor: 7.396

5.  Expression of cyclooxygenase-2 in human gastric carcinoma.

Authors:  A Ristimäki; N Honkanen; H Jänkälä; P Sipponen; M Härkönen
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 6.  Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

Authors:  F Garrido; F Ruiz-Cabello; T Cabrera; J J Pérez-Villar; M López-Botet; M Duggan-Keen; P L Stern
Journal:  Immunol Today       Date:  1997-02

7.  Human lung carcinomas express Fas ligand.

Authors:  G A Niehans; T Brunner; S P Frizelle; J C Liston; C T Salerno; D J Knapp; D R Green; R A Kratzke
Journal:  Cancer Res       Date:  1997-03-15       Impact factor: 12.701

8.  Local inhibition of natural killer cell activity promotes the progressive growth of intraocular tumors.

Authors:  R S Apte; E Mayhew; J Y Niederkorn
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-05       Impact factor: 4.799

9.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  317 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

2.  Antigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytes.

Authors:  Xue-Feng Bai; Jinqing Liu; Ou Li; Pan Zheng; Yang Liu
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 3.  Immunology of B7-H1 and its roles in human diseases.

Authors:  Hideto Tamura; Kiyoyuki Ogata; Haidong Dong; Lieping Chen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

4.  Development of effective immunotherapy for the treatment of patients with cancer.

Authors:  Steven A Rosenberg
Journal:  J Am Coll Surg       Date:  2004-05       Impact factor: 6.113

Review 5.  Shedding light on immunotherapy for cancer.

Authors:  Steven A Rosenberg
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

Review 6.  Biobehavioral factors and cancer progression: physiological pathways and mechanisms.

Authors:  Susan K Lutgendorf; Anil K Sood
Journal:  Psychosom Med       Date:  2011-10-21       Impact factor: 4.312

Review 7.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

8.  Lentivirus-mediated bifunctional cell labeling for in vivo melanoma study.

Authors:  Chi-Ping Day; John Carter; Carrie Bonomi; Dominic Esposito; Bruce Crise; Betty Ortiz-Conde; Melinda Hollingshead; Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-19       Impact factor: 4.693

9.  Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

Authors:  Steven A Rosenberg; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne L Topalian; Nicholas P Restifo; Armando Filie; Richard Chang; Mark E Dudley
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

10.  Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.

Authors:  Simon Turcotte; Alena Gros; Eric Tran; Chyi-Chia R Lee; John R Wunderlich; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.